Samprada & Nanhamati Singh Family Trust has submitted a letter to Exchange on amendment to trust deed under Regulation 11(5) of The Securities and Exchange Board of India (Substantial ....
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Midcap 150 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Samprada and Nanhamati Singh Family Trust, a promoter group entity of Alkem Laboratories, sold 0.46% shares of the company on 2 June 2026. The proceeds from this sale were distributed to the beneficiaries of the Trust. As a result, the Trust's shareholding in Alkem Laboratories has reduced from 18.74% to 18.28%. This disclosure is being made under SEBI's Regulation 11(5) of the Takeover Regulations, 2011, as required by the exemption order granted to the Trust in 2017. The Trust continues to hold a significant stake in the company post this sale.
This is a small stake sale of less than 0.5% by a promoter-affiliated Trust, so the immediate impact on the stock is likely minimal. However, it signals some distribution of wealth to Trust beneficiaries and a marginal dilution in promoter group holding.